KRAS and neoplasm: MRTX1133, a non-covalent KRAS-G12D inhibitor developed in 2021, has shown promise in preclinical studies by inhibiting KRAS nucleotide exchange and RAF1 binding, reversing early PDAC growth, and positively altering the tumor microenvironment [25,26,27].